U.S. Personal Products Stock News

Lowe's Companies (NYSE:LOW) has launched a creator driven marketing initiative in partnership with MrBeast. The company is building a Creator Network to work directly with digital creators and reach younger, next generation consumers. The effort focuses on using influencer content to shape purchasing inspiration and home improvement engagement beyond traditional advertising. Lowe's Companies, trading at $236.03, is adding a new layer to its customer outreach by pairing its established home...

Wondering whether BlackLine at around US$37.56 is starting to look appealing on value or still has work to do before it earns a spot on your watchlist. The stock has had a mixed run, with a 15.5% gain over the last 30 days, set against a 30.2% decline year to date and a 25.2% decline over the past year. Recent share price moves sit against a broader backdrop of ongoing attention on software names and how consistently they can convert adoption into durable cash flows. For BlackLine, many...

Earlier this week, Ocugen announced positive 12‑month Phase 2 ArMaDa data for its one‑time gene therapy OCU410 in geographic atrophy secondary to dry age‑related macular degeneration, showing a statistically significant 31% reduction in lesion growth at the optimal dose with a favorable safety profile. The company now plans a Phase 3 registrational trial starting in the third quarter of 2026, positioning OCU410 as a potential alternative to current therapies that require frequent, ongoing...

Morgan Stanley is preparing to launch its own Bitcoin ETF, ticker MSBT, giving clients a new way to gain exposure to Bitcoin. The product is expected to be available to the firm’s 16,000 financial advisors and wealth management clients once it goes live. This move reflects a broader push by Morgan Stanley into digital assets, including crypto infrastructure and regulatory engagement. Morgan Stanley, NYSE:MS, is taking a more direct step into cryptocurrencies with MSBT, a proprietary Bitcoin...

Executive change and why it matters for Fidelity National Financial stock Fidelity National Financial (FNF) has appointed Jeffrey Heighton as President of Enterprise Solutions, Agency, a move aimed at sharpening how its title agent network uses technology, outsourcing, and disciplined business management. For shareholders, this new role is directly tied to revenue strategy, expense management, and operational scale across the agency network. The appointment offers a fresh lens for thinking...

Investors may be wondering whether PC Connection at around US$58.52 is offering fair value today, or if the current price is out of line with what the business might be worth. The stock is up 2.7% over the last week and 2.9% year to date, but the 1 year return sits at a 5.9% loss, with 3 year and 5 year returns of 36.1% and 31.6% respectively. These moves come as PC Connection continues to feature in ongoing coverage of technology distributors and IT solutions providers, keeping it on the...

Abbott Laboratories (NYSE:ABT) executives outlined how pandemic-era coordination across office, manufacturing, and sales teams has shaped the company’s current culture. The leadership team highlighted that this alignment continues to influence talent acquisition and scientific work across Abbott’s global operations. The discussion focuses on people, processes, and culture rather than new product launches or financial transactions. For investors following Abbott primarily for its...

Ford Motor, ticker NYSE:F, faces multiple shareholder proposals in its 2026 proxy challenging unequal share voting rights and calling for more granular disclosure of voting results by share class. Investor groups including John Chevedden and the New York State Common Retirement Fund are pressing these governance changes ahead of Ford's May 14, 2026 annual meeting. Ford's board is urging shareholders to vote against the proposals, setting up a potential clash over corporate governance and...

Earlier this week, Bruker showcased new analytical instruments at the Analytica 2026 conference, including the iNTApharma system for cell and gene therapy, an expanded Fourier 80 Automation Suite for chemistry labs, and the TITAN handheld analyzer for industrial elemental analysis. The breadth of these launches underlines Bruker’s push to serve high-growth areas across biopharma, academic research, and industrial testing with more automated, application-focused tools. Next, we’ll examine how...

Why Autodesk Stock Is on Investors’ Radar Autodesk (ADSK) is back in focus after recent share price moves, with the stock up in the past month but lower over the past 3 months and year to date. This mixed return pattern is prompting investors to reassess how Autodesk’s US$7.2b in annual revenue and US$1.1b in net income line up against its current US$49.7b market value. See our latest analysis for Autodesk. Autodesk’s recent share price performance has been mixed, with an 8.6% 1 month share...

Coinbase Global stock snapshot after recent performance Coinbase Global (COIN) has seen mixed share performance recently, with a 4.3% one day decline and a 14.6% drop over the past week, in contrast with gains over the past month. See our latest analysis for Coinbase Global. At a share price of US$173.38, Coinbase Global’s short term share price return has weakened with a 14.6% decline over the past week, while the 3 year total shareholder return of 170.23% points to a very different long...

Recent legal action against Kyndryl Holdings (KD) has expanded securities class allegations around the company’s past free cash flow disclosures, and fresh internal control concerns together with SEC document requests are now sharpening investor focus on risk. See our latest analysis for Kyndryl Holdings. The legal and internal control issues arrive after a sharp reset in sentiment, with a 30 day share price return of 10.04% following a 90 day share price return decline of 52.90% and a 1 year...

If you are wondering whether Janus Henderson Group at around US$51.39 is offering fair value or hiding a margin of safety, the starting point is understanding what the current market price is really implying. The stock price has been steady over the last 7 days, with returns of 0.0%, while the 30 day return is 3.3%, the year to date return is 7.6%, and the 1 year return is 42.8%. This gives useful context before testing how those moves stack up against the underlying valuation. Recent...

Genius Sports (GENI) has moved closer to the center of sports advertising after expanding its Moment Engine across partners that the company says cover about 90% of the programmatic ad market, ahead of major global tournaments. See our latest analysis for Genius Sports. Despite the expanded reach of Moment Engine and new partnerships with agencies, broadcasters and the Pac-12, Genius Sports’ recent share price performance has been weak. The 30 day share price return is 24.49% and the 1 year...

Wondering if Celsius Holdings at around US$35.59 is a bargain or already pricing in a lot of optimism? This article walks you through the key signals behind the current price. The stock has had a choppy spell, with a 17.2% decline over the last 7 days, a 29.8% decline over 30 days, and a 25.5% decline year to date, even though the 1 year return sits at 1.3% and the 3 year and 5 year figures are 16.8% and a very large gain respectively. Recent coverage has focused on Celsius Holdings as a...

IBM (NYSE:IBM) and research partners report a quantum computing breakthrough, using current hardware to simulate real magnetic materials. The quantum simulations align with neutron scattering experiment data, indicating practical scientific use for existing quantum systems. The work points to potential applications in materials science, energy research, and medicine that are difficult to study with classical computers. For investors following NYSE:IBM, this update sits at the intersection...

Why Berkshire Hathaway is on investors’ radar today Berkshire Hathaway (BRK.B) is drawing fresh attention after recent share price softness, with the stock showing negative returns over the past month, past 3 months, year to date, and over the past year. For investors, that pullback, alongside a market value of about US$1.03b and a broad mix of operating businesses and investments, raises questions about how to think about Berkshire’s scale, recent financial trends, and current valuation. See...

Earlier this week, Arm Holdings unveiled the Arm AGI CPU, its first Arm-designed AI data center chip built on Neoverse CSS V3, marking the company’s move from pure IP licensing into supplying production silicon alongside partners such as Meta. This shift positions Arm closer to its hyperscale customers’ infrastructure spend, potentially altering how it earns revenue from AI workloads and custom silicon over time. We’ll now examine how Arm’s entry into selling its own AGI CPU silicon could...

Becton Dickinson recently presented at the 2026 Life Science Intelligence Summit and secured FDA 510(k) clearance for its Surgiphor 1000mL antimicrobial irrigation system, underscoring its push into specialized medtech solutions following the spin-off of its Biosciences and Diagnostics Solutions business. These moves highlight Becton Dickinson’s effort to reposition itself as a focused medical technology company built around innovation and productivity, even as analysts flag softer revenue...

If you are wondering whether Tronox Holdings is attractively priced or looking stretched, the recent share price moves give some important clues about where value might sit today. The stock last closed at US$9.01, with returns of 22.3% over 7 days, 25.8% over 30 days, 111.0% year to date and 31.8% over 1 year, while the 3 year and 5 year returns sit at 26.8% and 43.3% declines. Recent coverage has focused on how Tronox fits into the wider materials sector and what shifting expectations for...

What Aurinia Pharmaceuticals offers and where it stands today Aurinia Pharmaceuticals (AUPH) focuses on therapies for autoimmune diseases, anchored by its LUPKYNIS treatment for lupus nephritis. The company reported revenue of $283.055 million and net income of $287.202 million in the latest reported period. See our latest analysis for Aurinia Pharmaceuticals. Aurinia’s share price has been volatile in recent months, with a 1-day share price return of 1.60% and 7-day return of 3.77%, while...

In recent weeks, Axon Enterprise has seen strong demand for its AI-powered public safety tools and drones, alongside rising bookings for long-term contracts and mounting anticipation around an upcoming earnings release that analysts expect to show earnings per share growth. An interesting shift is how Axon’s expanding role in AI-driven situational awareness and defense-related applications is tying its growth prospects more closely to government spending priorities and conflict-related...

Viking Therapeutics (NasdaqCM:VKTX) has completed patient enrollment in its Phase 3 VANQUISH-2 trial for VK2735. The trial is evaluating VK2735, a dual GLP-1/GIP agonist, in obesity and type 2 diabetes. This milestone moves VK2735 further along Viking's clinical development path as of 2026. For you as an investor, the VANQUISH-2 enrollment milestone puts fresh attention on Viking Therapeutics, a clinical-stage company focused on metabolic and endocrine diseases. VK2735 sits within the...

Wondering whether SailPoint at US$12.28 is starting to look interesting or still too expensive for the risk you are taking. The stock has been under pressure, with a 0.5% decline over the last 7 days, 6.4% over the last month, and a year to date return of 35.2% and 40.2% over the past year. These moves are occurring as the market continues to reassess software names and focus more closely on business quality, balance sheet strength, and cash generation. For SailPoint, this context matters...